Johnson & Johnson (NYSE:JNJ) Stock Jumps 1.4% - Here's What Happened

Key Points

• Johnson & Johnson shares rose 1.4% after Guggenheim, RBC and other analysts reiterated positive ratings or raised price targets; the consensus target is $276.22, indicating additional potential upside.
• Pipeline momentum supported investor sentiment: the Tecvayli–Talvey combination cut progression or death risk by 89% in a Phase 3 multiple myeloma trial, while two-year ICOTYDE data showed sustained psoriasis clearance and consistent safety.
• J&J’s latest quarter beat earnings and revenue estimates, with sales up 6.6% year over year, and the company continues to offer a 2.1% dividend yield. Key risks include MedTech weakness, biosimilar and patent-cliff competition, and ongoing talc litigation.

Johnson & Johnson (NYSE:JNJ - Get Free Report) shares shot up 1.4% during mid-day trading on Wednesday. The company traded as high as $260.68 and last traded at $258.2460. 5,276,486 shares traded hands during trading, a decline of 34% from the average daily volume of 7,971,527 shares. The stock had previously closed at $254.78.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Analyst support: Guggenheim reaffirmed its “Buy” rating and set a $287 price target, implying roughly 11% upside from the referenced trading level. RBC Capital also maintained its “Buy” rating. RBC Capital keeps its Buy rating on Johnson & Johnson
• Positive Sentiment: Multiple myeloma progress: Johnson & Johnson reported that the combination of Tecvayli and Talvey reduced the relative risk of disease progression or death by 89% and the risk of death by 62% in the Phase 3 MonumenTAL-6 trial. The results support the potential expansion of J&J’s oncology portfolio, although the combination remains subject to regulatory and commercial development. 2026 cancer treatment advances
• Positive Sentiment: Psoriasis drug durability: Two-year Phase 3 data for oral ICOTYDE showed maintained skin clearance and consistent safety through Week 112, strengthening the case for the drug as a targeted treatment option in difficult-to-treat plaque psoriasis.
• Positive Sentiment: Innovative Medicines momentum: RBC commentary indicated that growth in J&J’s Innovative Medicine segment is helping offset weakness in MedTech, improving confidence in the company’s earnings and replacement-product pipeline. Innovative Medicines momentum
• Neutral Sentiment: Dividend appeal versus valuation: J&J recorded its 64th consecutive year of dividend growth, supporting its defensive-income profile. However, the investment case remains balanced against biosimilar competition, a MedTech slowdown and ongoing talc litigation. Johnson & Johnson dividend analysis
• Negative Sentiment: MedTech and patent-cliff risks: Analysts continue to watch competitive pressure, including Abiomed, and the possibility that upcoming patent expirations could test J&J’s ability to replace lost product revenue. J&J MedTech outlook

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on JNJ shares. Scotiabank reiterated an "outperform" rating and set a $305.00 price target on shares of Johnson & Johnson in a report on Thursday, July 16th. Guggenheim reaffirmed a "buy" rating and set a $287.00 price objective on shares of Johnson & Johnson in a research report on Wednesday. Weiss Ratings raised shares of Johnson & Johnson from a "buy (b-)" rating to a "buy (b)" rating in a research report on Friday, July 24th. Royal Bank Of Canada increased their price target on shares of Johnson & Johnson from $287.00 to $290.00 and gave the stock an "outperform" rating in a research note on Tuesday. Finally, Morgan Stanley raised their price target on shares of Johnson & Johnson from $284.00 to $294.00 and gave the company an "overweight" rating in a report on Thursday, July 16th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $276.22.

Johnson & Johnson Trading Up 1.4%

The stock has a market capitalization of $622.35 billion, a price-to-earnings ratio of 29.92, a price-to-earnings-growth ratio of 2.48 and a beta of 0.21. The company has a current ratio of 1.09, a quick ratio of 0.81 and a debt-to-equity ratio of 0.44. The company has a fifty day moving average of $265.86 and a two-hundred day moving average of $248.63.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings results on Wednesday, July 15th. The company reported $2.90 EPS for the quarter, beating the consensus estimate of $2.84 by $0.06. Johnson & Johnson had a return on equity of 32.42% and a net margin of 21.48%.The company had revenue of $25.31 billion for the quarter, compared to the consensus estimate of $25.06 billion. During the same quarter last year, the company posted $2.77 earnings per share. The company's revenue for the quarter was up 6.6% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. On average, research analysts expect that Johnson & Johnson will post 11.54 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th were given a dividend of $1.34 per share. The ex-dividend date of this dividend was Tuesday, August 25th. This represents a $5.36 dividend on an annualized basis and a yield of 2.1%. Johnson & Johnson's payout ratio is currently 62.11%.

Insiders Place Their Bets

In other news, EVP Vanessa Broadhurst sold 23,054 shares of Johnson & Johnson stock in a transaction dated Monday, July 20th. The stock was sold at an average price of $251.27, for a total value of $5,792,778.58. Following the transaction, the executive vice president directly owned 23,003 shares in the company, valued at approximately $5,779,963.81. The trade was a 50.06% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Elizabeth Forminard sold 15,918 shares of the business's stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $257.00, for a total value of $4,090,926.00. Following the transaction, the executive vice president directly owned 16,994 shares of the company's stock, valued at $4,367,458. This represents a 48.37% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 87,569 shares of company stock valued at $23,064,544. 0.16% of the stock is owned by company insiders.

Hedge Funds Weigh In On Johnson & Johnson

Large investors have recently bought and sold shares of the stock. Outlook Capital Management LLC acquired a new stake in Johnson & Johnson in the 2nd quarter worth $28,000. Matrix Trust Co lifted its stake in shares of Johnson & Johnson by 56.2% in the second quarter. Matrix Trust Co now owns 150 shares of the company's stock valued at $38,000 after buying an additional 54 shares during the period. Montgomery Financial Services LLC acquired a new stake in Johnson & Johnson during the second quarter worth about $43,000. Hyposwiss Advisors SA bought a new position in Johnson & Johnson during the fourth quarter valued at about $42,000. Finally, Polaris Financial Partners acquired a new position in Johnson & Johnson in the 3rd quarter valued at approximately $56,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

About Johnson & Johnson

Johnson & Johnson NYSE: JNJ is a global healthcare company that develops, manufactures and markets products through two primary business segments: Innovative Medicine and MedTech. Its operations serve patients, healthcare professionals and consumers in markets around the world.

The Innovative Medicine segment focuses on prescription medicines in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.